Skip to content
Adjuvance Technologies

Adjuvance Technologies

Empowering health.

  • About Us
  • Our Technology
  • Our Leadership
    • Board of Directors
    • Management Team
  • Investors & Media
  • Contact

Enhancing the Immunogenicity of Cancer Vaccines with QS21

By jgardnerAugust 20, 2011Publications
Enhancing the Immunogenicity of Cancer Vaccines with QS21

Adjuvance co-founder David Gin describes the clinical use of QS-21 as an adjuvant in developing and enhancing cancer vaccines.

Gin_slovin_nihms600845

Post navigation

Preclinical Evaluation of the Synthetic Adjuvant SQS-21 and its Constituent Isomeric Saponins
XCONOMY

Recent Posts

  • ADJUVANCE TECHNOLOGIES ANNOUNCES NIH FUNDING FOR COVID-19 VACCINE RESEARCH
  • ADJUVANCE TECHNOLOGIES ANNOUNCES $20 MILLION SERIES A INVESTMENT FROM MORNINGSIDE VENTURE INVESTMENTS
  • Comparative preclinical evaluation of AS01 versus other Adjuvant systems in a candidate herpes zoster glycoprotein E subunit vaccine
  • NEJM Reports Efficacy of QS-21 Containing Herpes Zoster Subunit Vaccine
  • Vaccine Adjuvant Systems containing monophosphoryl lipid A andQS-21 induce strong humoral and cellular immune responses against hepatitis B surface antigen which persist for at least 4 years after vaccination
Copyright © All rights reserved. Theme Businessbiz by Sensational Theme